Listing analysis and research matching GE:
India and China's biogeneric and vaccine strengths
Today many biotechnology analysts are pointing to China and India as becoming strategically important for biotechnology growth and investment. For the forseeable future the strength of Indian and Chinese biotechnology will be confined to the area of generics and vaccines where they have already established some strengths
NDA applications continue to decline in 2006
Between 1996 and 2006 the number of new drug applications (NDAs) approved by the US FDA declined by 10 percent, dropping from 289 to 259. Silico Research's analysis of FDA and USPTO's databases shows that this fall has been accompanied by a reduction in the number of out-licensed drugs. An examination of a random selection of NDAs in 1996 and 2006 shows that the number of out licensed drugs dropped from 59 to 36 in this period, a decline of 30%.
Amgen tries its hand at venture capital
Over the past ten years a number of large biopharmaceutical companies have established venture funds to help small start-up biotechnology companies. The aim of these funds is to find new ideas, products and technology platforms to supplement internal research and development and boost product pipelines. One such fund was set up by Amgen in 2004. Formed as part of Amgen's outreach licensing programme and known as Amgen Ventures, this fund, which has $100 million in available funds, focuses on helping emerging biotechnology companies working in human therapies that match Amgen's areas of interest: oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience and cardiovascular.
GE Healthcare alliances in the medical devices and diagnostic market
GE Healthcare, a $17 billion unit of General Electric Company, has an active alliance programme in a range of technologies covering medical imaging, healthcare IT, diagnostic imaging agents, patient monitoring, drug discovery and protein separation.
GE and Lilly ink cancer diagnostics linkup
In a sign of the accelerating convergence between treatments and diagnostics GE and Eli Lilly have announced a collaboration to develop in vitro diagnostic assays that may help predict cancer treatment response to targeted therapies.
BioPartnering 2008
The terms of a deal on offer, a partner's development expertise and their alliance management skills are the top drivers of alliance formation according to senior partnering business development executives in the pharmaceutical, biotechnology and medical devices industry and research institutes who participated in the BioPartnering 2008 survey.
